| Investor | Pontifax Management 4 G.p. (2015) Ltd. |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Pontifax Management 4 G.p. (2015) Ltd. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2025-04-18 |
|
KROS / Keros Therapeutics, Inc. | 4,734,507 | 4,787,331 | ||||
| 2024-11-05 |
|
NVCT / Nuvectis Pharma, Inc. | 917,400 | 288,873 | ||||
| 2024-02-06 |
|
NVCT / Nuvectis Pharma, Inc. | 917,400 | |||||
| 2020-04-23 |
|
KROS / Keros Therapeutics, Inc. | 4,734,507 | |||||
| 2019-09-19 |
|
ARQL / ArQule, Inc. | 2,238,000 | 8,844,587 | ||||
| 2018-06-28 |
|
ARQL / ArQule, Inc. | 2,238,000 | 8,392,000 | ||||
| 2018-06-27 |
|
ARQL / ArQule, Inc. | 2,238,000 | |||||
| 2018-01-02 |
|
ELOX / Eloxx Pharmaceuticals, Inc. | 7,188,186 | |||||
| 2017-12-29 |
|
ELOX / Eloxx Pharmaceuticals, Inc. | 4,900,249 |
